4-carbamoylimidazolium 5-olate has been researched along with Myelodysplastic Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirano, M; Kimura, K; Masaoka, T; Ogawa, M; Ohno, R; Uzuka, Y; Yamada, K | 1 |
| Saito, Y; Uzuka, Y | 1 |
1 trial(s) available for 4-carbamoylimidazolium 5-olate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Child; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lymphoma; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Polycythemia Vera; Remission Induction | 1989 |
1 other study(ies) available for 4-carbamoylimidazolium 5-olate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Treatment of myelodysplastic syndrome using SM-108 in relation to stem cell kinetics].
Topics: Adult; Aged; Cell Cycle; Drug Administration Schedule; Female; Hematopoietic Stem Cells; Humans; Imidazoles; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 1988 |